PPARγ agonists appear to be useful in reversing this early stage of the renal fibrosis (epithelial-mesenchymal transition, EMT) in the condition of the high glucose and to restore the function of SGLT-proteins mediated glucose uptake [56, 60]. Here, PPARG is linked to renal fibrosis.